摘要
目的:分析新辅助治疗联合程序性死亡蛋白-1(PD-1)抑制剂在局部进展期结直肠癌患者中的应用效果。方法:本文为前瞻性研究,选择2023年6月—2025年1月阳江市人民医院肿瘤一科接诊的局部进展期结直肠癌患者60例为对象,用信封法分为两组,各30例。对照组采用FOLFOX6进行新辅助化疗,观察组在对照组基础上联合PD-1抑制剂(信迪利单抗注射液)治疗。比较两组肛肠动力学、肿瘤标志物及毒副反应发生率。结果:两组治疗后肛肠动力学水平均改善,观察组肛管最大收缩压(MSP)、肛管静息压(ARP)及最大耐受容量(MTV)大于对照组,直肠肛管抑制反射阈值(AIRT)及直肠静息压(RRP)小于对照组(P<0.05)。两组治疗后肿瘤标志物均降低,观察组糖类抗原19-9(CA19-9)、癌胚抗原(CEA)水平低于对照组(P<0.05)。两组毒副反应发生率比较,差异无统计学意义(P>0.05)。结论:新辅助治疗联合PD-1抑制剂能改善局部进展期结直肠癌患者肛肠动力学水平,降低肿瘤标志物水平,且不增加毒副反应。
Objective:To analyze the application effect of neoadjuvant therapy combined with programmed death protein-1(PD-1)inhibitors in patients with locally advanced colorectal cancer.Method:This article was a prospective study.Sixty patients with locally advanced colorectal cancer who were admitted to Department of OncologyⅠ,People's Hospital of Yangjiang from June 2023 to January 2025 were selected as the subjects and divided into two groups by the envelope method,with 30 cases in each group.The control group received neoadjuvant chemotherapy with FOLFOX6,and the observation group was treated with PD-1 inhibitor(Sintilimab Injection)on the basis of the control group.The anorectal dynamics,tumor markers and the incidence of toxic and side effects between the two groups were compared.Result:After treatment,the anorectal dynamics levels were improved in both groups,the maximum systolic blood pressure(MSP),anal resting pressure(ARP)and maximum tolerated volume(MTV)in the observation group were larger than those in the control group,and the anorectal inhibitory reflex threshold(AIRT)and rectal resting pressure(RRP)were lower than those in the control group(P<0.05).After treatment,the tumor markers were decreased in both groups,the levels of carbohydrate antigen 19-9(CA19-9),carcinoembryonic antigen(CEA)in the observation group were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of toxic and side effects between the two groups(P>0.05).Conclusion:Neoadjuvant therapy combined with PD-1 inhibitors can improve the anorectal dynamics levels of locally advanced colorectal cancer patients,reduce the tumor markers levels,and does not increase the toxic and side effects.
作者
叶天允
YE Tianyun(Department of OncologyⅠ,People's Hospital of Yangjiang,Yangjiang 529500,China)
出处
《中国医学创新》
2025年第31期39-42,共4页
Medical Innovation of China
